Indication1

NUEDEXTA (dextromethorphan HBr and quinidine sulfate) is indicated for the treatment of pseudobulbar affect (PBA).

PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent with the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

NUEDEXTA is the first and only FDA-approved treatment for PBA1

PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, including2-4

  • Dementias, including Alzheimer’s disease (AD)
  • Stroke
  • Traumatic brain injury (TBI)
 
  • Multiple sclerosis (MS)
  • Parkinson’s disease (PD)
  • Amyotrophic lateral sclerosis (ALS)